Darinaparsin is an investigational drug.
There have been 12 clinical trials for Darinaparsin.
The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2007.
The most common disease conditions in clinical trials are Lymphoma, Lymphoma, T-Cell, Peripheral, and Lymphoma, T-Cell. The leading clinical trial sponsors are Ziopharm, Solasia Pharma K.K., and Synex Consulting Korea Ltd.